Spirocyclic degronimers for target protein degradation

1. A method for treating a human with a cancer mediated by a Targeted Protein selected from ABL, BRD4, BRD9, CBP, DOT1L, ERK1, ERK2, EZH2, FGFR3, FGFR4, FKBP, MDM2, NTRK1, PIK3CA, RET, WDR5, EGFR, bromodomain containing protein, glucocorticoid receptor, androgen receptor, and estrogen receptor, comprising administering an effective amount of a compound optionally in a pharmaceutically acceptable carrier, to a patient in need thereof, wherein the compound is of Formula:

or a pharmaceutically acceptable salt thereof;

wherein:

W 1 is C═O;

W 2 is C═O;

X is independently NH, NR 12 , CH 2 , CHR 12 , C(R 12 ) 2 , O, or S;

n is 0, 1, 2, or 3;

is a single or double bond;

Y and Z are each independently selected from the group consisting of CH 2 , CHR 12 , C(R 12 ) 2 , C(O), N, NH, NR 13 , O, S, and S(O) as permitted by valency;

R 7 and R 8 , are independently selected from the group consisting of hydrogen, alkyl, aliphatic, heteroaliphatic, aryl, heteroaryl, carbocyclic, hydroxyl, alkoxy, amine, —NHalkyl, and —Nalkyl 2 ;

or R 7 and R 8 form a 3-, 4-, 5-, or 6-membered spirocarbocycle, or a 4-, 5-, or 6-membered spiroheterocycle comprising 1 or 2 heteroatoms selected from N and O;

R 5 is selected at each instance from the group consisting of: alkyl, alkene, alkyne, halogen, hydroxyl, alkoxy, azide, amino, cyano, aryl, heteroaryl, heteroaliphatic, hetercyclic, —NHalkyl, —N(alkyl) 2 , —NHSO 2 alkyl, —N(alkyl)SO 2 alkyl, —NHSO 2 aryl, aliphatic, —N(alkyl)SO 2 aryl, —NHSO 2 alkenyl, —N(alkyl)SO 2 alkenyl, —NHSO 2 alkynyl, —N(alkyl)SO 2 alkynyl, and haloalkyl;

or two R 5 substituents together with the carbon atom(s) to which they are bound can form a 3, 4, 5 or 6 membered ring;

R 6 is a bond wherein Y or Z is substituted with R 10 ;

or R 6 is a divalent moiety attached to Y and Z that contains 1 to 5 contiguous carbon atoms that form a 3 to 8-membered ring wherein 1, 2, or 3 carbon atoms can be replaced with a nitrogen, oxygen or sulfur atom wherein one of the ring atoms is substituted with R 10 and the others are optionally substituted with R 11 ;

wherein the contiguous atoms of R 6 can be attached through a single or double bond;

or

forms a bicyclic moiety which is substituted with R 10 and optionally substituted with one or more groups independently selected from R 11 and oxo;

R 10 is Linker-Targeting Ligand;

R 11 is selected at each instance from the group consisting of: hydrogen, alkyl, alkenyl, alkynyl, aliphatic, heteroaliphatic, carbocyclic, halogen, hydroxyl, amino, cyano, alkoxy, aryl, heteroaryl, heterocyclic, carbocyclic, alkylamino, alkylhydroxyl, and haloalkyl;

R 12 is selected from the group consisting of alkyl, alkene, alkyne, halogen, hydroxyl, alkoxy, azide, amino, —C(O)H, —C(O)OH, —C(O)(aliphatic), —C(O)O(aliphatic), —NH(aliphatic), —N(independently aliphatic) 2 , —NHSO 2 alkyl, —N(alkyl)SO 2 alkyl, —NHSO 2 aryl, —N(alkyl)SO 2 aryl, —NHSO 2 alkenyl, —N(alkyl)SO 2 alkenyl, —NHSO 2 alkynyl, —N(alkyl)SO 2 alkynyl, aliphatic, heteroaliphatic, aryl, heteroaryl, heterocyclic, carbocyclic, cyano, nitro, nitroso, —SH, —Salkyl, and haloalkyl;

R 13 is selected from the group consisting of alkyl, alkenyl, alkynyl, —C(O)H, —C(O)OH, —C(O)alkyl, and —C(O)Oalkyl;

Linker is a chemical group that covalently attaches the Degron to the Targeting Ligand;

and Targeting Ligand binds to the Targeted Protein.

2. The method of claim 1 , wherein X is NH.

3. The method of claim 1 , wherein n is 0.

4. The method of claim 1 , wherein X is NH and n is 0.

5. The method of claim 1 , wherein R 7 and R 8 are hydrogen.

6. The method of claim 1 , wherein R 6 is a divalent moiety attached to Y and Z that contains 1 to 5 contiguous carbon atoms that form a 3 to 8-membered ring wherein 1, 2, or 3 carbon atoms can be replaced with a nitrogen, oxygen or sulfur atom wherein one of the ring atoms is substituted with R 10 and the others are optionally substituted with R 11 ; wherein the contiguous atoms of R 6 can be attached through a single or double bond.

7. The method of claim 1 , wherein

forms a bicyclic moiety which is substituted with R 10 and optionally substituted with one or more groups independently selected from R 11 and oxo.

8. The method of claim 1 , wherein

is selected from:

9. The method of claim 1 , wherein the cancer is a solid tumor.

10. The method of claim 1 , wherein the cancer is a hematological cancer.

11. The method of claim 1 , wherein the cancer is multiple myeloma.

12. The method of claim 1 , wherein the cancer is leukemia.

13. The method of claim 1 , wherein the cancer is T-cell lineage acute lymphoblastic leukemia.

14. The method of claim 1 , wherein the cancer is large granular lymphocytic leukemia.

15. The method of claim 1 , wherein the cancer is Hodgkin's lymphoma.

16. The method of claim 1 , wherein the cancer is non-Hodgkin's lymphoma.

17. The method of claim 1 , wherein the cancer is sarcoma.

18. The method of claim 1 , wherein the cancer is synovial sarcoma.

19. The method of claim 1 , wherein the cancer is Ewing's sarcoma, hemangiosarcoma, Kaposi's sarcoma, liposarcoma, or myosarcoma.

20. The method of claim 1 , wherein the Linker is:

wherein:

X 1 and X 2 are independently selected from bond, NH, NR 25 , CH 2 , CHR 25 , C(R 25 ) 2 , O, and S;

R 20 , R 21 , R 22 , R 23 , and R 24 are independently selected from heteroarylalkyl, aryl, arylalkyl, heterocycle, aliphatic, heteroaliphatic, heteroaryl, polypropylene glycol, lactic acid, glycolic acid, carbocycle, bond, alkyl, —C(O)— —C(O)O—, —OC(O)—, —C(O)alkyl, —C(O)Oalkyl, —C(S)—, —SO 2 —, —S(O)—, —C(S)—, —C(O)NH—, —NHC(O)—, —N(alkyl)C(O)—, —C(O)N(alkyl)-, —O—, —S—, —NH—, —N(alkyl)-, —CH(—O—R 26 )—, —CH(—NHR 25 )—, —CH(—NH 2 )—, —CH(—NR 25 2 )—, —C(—O—R 26 )alkyl-, —C(—NHR 25 )alkyl-, —C(—NH 2 )alkyl-, —C(—NR 25 2 )alkyl-, -alkyl(R 27 )-alkyl(R 28 )—, —C(R 27 R 28 )—, —P(O)(OR 26 )O—, —P(O)(OR 26 )—, —NHC(O)NH—, —N(R 25 )C(O)N(R 25 )—, —N(H)C(O)N(R 25 )—, polyethylene glycol, poly(lactic-co-glycolic acid), alkene, haloalkyl, alkoxy, and alkyne,

R 25 is selected at each instance from alkyl, —C(O)H, —C(O)OH, —C(O)alkyl, —C(O)Oalkyl, alkenyl, and alkynyl;

R 26 is hydrogen, alkyl, arylalkyl, heteroarylalkyl, alkene, alkyne, aryl, heteroaryl, heterocyclic, aliphatic, or heteroaliphatic; and

R 27 and R 28 are independently selected from hydrogen, alkyl, amine, or together with the carbon atom to which they are attached, form C(O), C(S), C═CH 2 , a C 3 -C 6 spirocarbocycle, or a 4-, 5-, or 6-membered spiroheterocycle comprising 1 or 2 heteroatoms selected from N and O.

21. The method of claim 20 , wherein the Linker is selected from:

22. The method of claim 20 , wherein the Linker is selected from:

23. The method of claim 1 , wherein the compound is administered as a solid pharmaceutical composition.

24. The method of claim 1 , wherein the compound is administered parenterally.

25. The method of claim 1 , wherein the compound is administered intravenously.

26. The method of claim 1 , wherein the compound is administered orally.